Evidence of Inhaled Tobramycin in Non-cystic Fibrosis Bronchiectasis

Overview

Journal Open Respir Med J

Publisher Bentham Open

Specialty Pulmonary Medicine

Date 2015 Apr 21

PMID 25893022

Citations 6

Authors

Montserrat Vendrell

Gerard Munoz

Javier De Gracia

Affiliations

Soon will be listed here.

Abstract

There is currently less experience with inhaled tobramycin in non-cystic fibrosis bronchiectasis than in cystic fibrosis (CF). Intravenous formulation and solution for inhalation (TSI) have been studied in non-CF bronchiectasis patients with chronic P. aeruginosa bronchial infection. An improvement in clinical parameters and a reduction in bacterial density have been shown with both inhaled solutions in these patients. However, further trials are needed to determine the most effective dose and administration protocol in these patients. Based on the current evidence, recommendations cannot be made regarding the use of TSI to treat exacerbations. Although no systemic toxicity has been reported in studies specifically investigating this treatment, patients with known kidney disease or ear disorders should be treated with caution. Adverse respiratory effects are reported to be more common in non-CF patients than in CF patients, who tend to be non-smokers and younger. Research is being conducted into the possibility of combining tobramycin with other antibiotics to increase its antibacterial activity. In this review we will present and discuss the published evidence regarding the use of inhaled tobramycin in non-CF bronchiectasis.

Citing Articles

Opportunistic etiological agents causing lung infections: emerging need to transform lung-targeted delivery.

Debnath S, Debnath M, Srivastava R Heliyon. 2023; 8(12):e12620.

PMID: 36619445 PMC: 9816992. DOI: 10.1016/j.heliyon.2022.e12620.

Tobramycin Serum Concentrations in Tracheostomy-Dependent Children Receiving Inhaled Tobramycin.

Hughes K, Cristea A, Tillman E Pediatr Allergy Immunol Pulmonol. 2022; 33(2):92-95.

PMID: 35921575 PMC: 8443261. DOI: 10.1089/ped.2020.1161.

The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis.

Al-Jahdali H, Alshimemeri A, Mobeireek A, Albanna A, Al Shirawi N, Wali S Ann Thorac Med. 2017; 12(3):135-161.

PMID: 28808486 PMC: 5541962. DOI: 10.4103/atm.ATM_171_17.

Inhaled Antibiotic Therapy in Chronic Respiratory Diseases.

Maselli D, Keyt H, Restrepo M Int J Mol Sci. 2017; 18(5).

PMID: 28509852 PMC: 5454974. DOI: 10.3390/ijms18051062.

Inhaled Antibiotics for Gram-Negative Respiratory Infections.

Wenzler E, Fraidenburg D, Scardina T, Danziger L Clin Microbiol Rev. 2016; 29(3):581-632.

PMID: 27226088 PMC: 4978611. DOI: 10.1128/CMR.00101-15.

References

Rosen M . Chronic cough due to bronchiectasis: ACCP evidence-based clinical practice guidelines. Chest. 2006; 129(1 Suppl):122S-131S. DOI: 10.1378/chest.129.1_suppl.122S. View

Tsang K, Tan K, Ho P, Ooi G, Ho J, Mak J . Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax. 2005; 60(3):239-43. PMC: 1747352. DOI: 10.1136/thx.2002.003236. View

Chalmers J, Hill A . Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol Immunol. 2012; 55(1):27-34. DOI: 10.1016/j.molimm.2012.09.011. View

Tre-Hardy M, Nagant C, El Manssouri N, Vanderbist F, Traore H, Vaneechoutte M . Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model. Antimicrob Agents Chemother. 2010; 54(10):4409-15. PMC: 2944582. DOI: 10.1128/AAC.00372-10. View

Lenney W, Edenborough F, Kho P, Kovarik J . Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects. J Cyst Fibros. 2010; 10(1):9-14. DOI: 10.1016/j.jcf.2010.08.019. View

Serisier D, Bilton D, Soyza A, Thompson P, Kolbe J, Greville H . Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax. 2013; 68(9):812-7. PMC: 4770250. DOI: 10.1136/thoraxjnl-2013-203207. View

Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M . Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect. 2011; 17 Suppl 6:E1-59. PMC: 7128977. DOI: 10.1111/j.1469-0691.2011.03672.x. View

Ahya V, Doyle A, Mendez J, Lipson D, Christie J, Blumberg E . Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient. J Heart Lung Transplant. 2005; 24(7):932-5. DOI: 10.1016/j.healun.2004.05.008. View

Sands D, Sapiejka E, Gaszczyk G, Mazurek H . Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS. J Cyst Fibros. 2014; 13(6):653-60. DOI: 10.1016/j.jcf.2014.04.006. View

10.

Standaert T, VanDevanter D, Ramsey B, Vasiljev M, Nardella P, Gmur D . The choice of compressor effects the aerosol parameters and the delivery of tobramycin from a single model nebulizer. J Aerosol Med. 2000; 13(2):147-53. DOI: 10.1089/089426800418677. View

11.

Haworth C, Foweraker J, Wilkinson P, Kenyon R, Bilton D . Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014; 189(8):975-82. PMC: 4098097. DOI: 10.1164/rccm.201312-2208OC. View

12.

Trapnell B, McColley S, Kissner D, Rolfe M, Rosen J, McKevitt M . Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Respir Crit Care Med. 2011; 185(2):171-8. PMC: 3361752. DOI: 10.1164/rccm.201105-0924OC. View

13.

Chalmers J, Smith M, McHugh B, Doherty C, Govan J, Hill A . Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012; 186(7):657-65. DOI: 10.1164/rccm.201203-0487OC. View

14.

Al-Aloul M, Nazareth D, Walshaw M . Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations. J Aerosol Med Pulm Drug Deliv. 2013; 27(4):299-305. DOI: 10.1089/jamp.2013.1055. View

15.

Scheinberg P, Shore E . A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest. 2005; 127(4):1420-6. DOI: 10.1378/chest.127.4.1420. View

16.

Hoffmann I, Rubin B, Iskandar S, Schechter M, Nagaraj S, Bitzan M . Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Pediatr Pulmonol. 2002; 34(5):375-7. DOI: 10.1002/ppul.10185. View

17.

Pasteur M, Bilton D, Hill A . British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010; 65 Suppl 1:i1-58. DOI: 10.1136/thx.2010.136119. View

18.

Martinez-Garcia M, De Gracia J, Vendrell Relat M, Giron R, Maiz Carro L, de la Rosa Carrillo D . Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J. 2013; 43(5):1357-67. DOI: 10.1183/09031936.00026313. View

19.

Poli G, Acerbi D, Pennini R, Soliani Raschini A, Corrado M, Eichler H . Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi. Paediatr Drugs. 2007; 9 Suppl 1:3-9. DOI: 10.2165/00148581-200709001-00002. View

20.

Chuchalin A, Amelina E, Bianco F . Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements. Pulm Pharmacol Ther. 2009; 22(6):526-32. DOI: 10.1016/j.pupt.2009.06.001. View